Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

COHANCE LIFESCIENCES LTD.

NSE : COHANCEBSE : 543064ISIN CODE : INE03QK01018Industry : Pharmaceuticals & DrugsHouse : Private

BSE1011.2088.1 (+9.54 %)

PREV CLOSE ( ) 923.10

OPEN PRICE ( ) 943.80

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 140049

TODAY'S LOW / HIGH ( )915.10 1038.00

52 WK LOW / HIGH ( )856.9 1359

NSE1012.9590.05 (+9.76 %)

PREV CLOSE( ) 922.90

OPEN PRICE ( ) 937.70

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 1012.95 (12565)

VOLUME 4938667

TODAY'S LOW / HIGH( ) 914.25 1038.90

52 WK LOW / HIGH ( )856.3 1360

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 06-11 2018

Management Info

Vivek Sharma - Chairman V Prasada Raju - Managing Director

Registered Office

Address 215 Atrium, C Wing, 8th Floor, 819-821,Andheri, Kurla Road, Chakala,Andheri (East), Chakala Midc,
Mumbai,
Maharashtra-400093

Phone 022-61539999

Email info@suvenpharm.com

Website www.suvenpharm.com

Registrars Details

K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)

Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad

Listing : BSE, NSE

NEWS

14Aug USFDA completes GMP inspection at Coha
United States Food and Drug Administration (USFDA) has completed a Good..

12Aug Cohance Lifesciences to invest $10 mil
Cohance Lifesciences (with its subsidiaries, hereafter referred to as ‘C..

20Jun Cohance Lifesciences enters into agree
Cohance Lifesciences has entered into an agreements with Chromo Laborato..

26May Cohance Lifesciences gains on receivin
Cohance Lifesciences is currently trading at Rs. 1094.55, up by 10.95 po..

26May Cohance Lifesciences receives EIR from
Cohance Lifesciences has received the Establishment Inspection Report (E..

Financials

Rs. in Millions

	QTR Jun 25	ANNUAL 25
Net Profit	525.7	2717.1
Gross Profit	710.4	3513.5
Operating Profit	1173	4165.5
Net Sales	4835.8	10935.1

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Procter&Gamble Healt (BSE) 6525.95 (0.94%)	M.Cap ( in Cr)10832.67
Haleos Labs (BSE) 1169.00 (4.52%)	M.Cap ( in Cr)353.42
Glaxosmithkline Phar (BSE) 2811.40 (1.48%)	M.Cap ( in Cr)47626.81
Caplin Point Lab (BSE) 2174.00 (1.76%)	M.Cap ( in Cr)16524.94
Fredun Pharma (BSE) 1325.30 (2.35%)	M.Cap ( in Cr)625.76

Shareholding Pattern

	PROMOTERS	66.41%
	NON-INSTITUTION	14.95%
	MUTUAL FUNDS/UTI	8.9%
	FI/BANKS/INSURANCE	2.27%
	GOVERNMENT	0.01%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
DSP Healthcare Fund...	7.88
ITI Pharma & Health...	4.53
Mirae Asset Healthc...	3.61
UTI Healthcare Fund...	2.81
HDFC Pharma and Hea...	2.24
Invesco India Focus...	2.17
DSP Focused Fund-Reg(G)	2.17

Risk Disclosures on Derivatives

Smart Quotes

COHANCE LIFESCIENCES LTD.